TLR Agonist Conjugates for Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating microbial infections, particularly viral and bacterial infections, face challenges due to viral interferon antagonists that block innate and adaptive immune responses, limiting the effectiveness of Toll-like Receptor (TLR) agonists in activating immune systems.
Innovation Solution
Development of broad-spectrum, long-lasting, non-toxic TLR agonist conjugates that enhance signal transduction by directing the pharmacophore to target cell endosomes, overcoming viral or bacterial obstruction of interferon production and modulating the innate immune system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR agonists are used to activate the immune system, then immune response is enhanced, but viral interferon antagonists block the immune response
Solution Approach 1:
The patent uses conjugates as intermediary structures that link TLR agonists to interferon antagonists. The conjugate structure allows the TLR agonist component to activate immune signaling while the interferon antagonist component is neutralized or redirected, preventing it from blocking the immune response. This mediator approach resolves the contradiction by combining both elements in a controlled configuration where they work together rather than oppose each other.
Solution Approach 2:
The patent merges TLR agonists and interferon antagonists into a single conjugate molecule. By combining these previously opposing elements into one structure, the invention allows the TLR agonist to stimulate immune response while the interferon antagonist portion is incorporated in a way that prevents it from blocking the response, thus resolving the contradiction through integration.
2Adaptability or versatility
If broad-spectrum immune activation is achieved, then coverage against multiple pathogens is improved, but specificity and targeted delivery may be reduced
Solution Approach 1:
The conjugate structure is designed with universal features that allow it to activate multiple TLR pathways simultaneously, providing broad-spectrum coverage against different pathogen types. The modular design enables a single conjugate structure to interact with various TLRs, achieving multi-functionality that covers viral, bacterial, and other pathogens while maintaining targeted delivery capabilities.
Data Source
AI summary
The present invention provides for TLR agonist conjugates (compounds) and compositions, as well as methods of using them. The compounds of the invention are broad-spectrum, long-lasting, and non-toxic combination of synthetic immunostimulatory agents, which are useful for activating the immune system of a mammal, preferably a human and can help direct the pharmacophore to the receptor within the endosomes of target cells and enhance the signal transduction induced by the pharmacophore.